All In Biotech

Drug Trial Radar · NCT03158090

The Longitudinal Approach to Acromegaly: A Pattern of Treatment and Comparative Effectiveness Research

Last checked: Nov 20, 2026Latest source record: Mar 16, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

1,965

Planned (sponsor's estimate)

Start

Dec 15, 2017

Primary completion

Dec 30, 2050

Study completion Jan 30, 2051

Sponsor

Lead sponsor
Ginkgo Leaf Center for Rare DisordersAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 17, 2017

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years

Summary

As written by the sponsor on the registry.

This study is a prospective, noninteractive, observational, and longitudinal study aimed at assessing the treatment pattern and clinical outcome of acromegaly in China.

Conditions

  • Acromegaly

Interventions

  • Transnasal butterfly surgeryProcedure

    The patient will be treated in accordance with the advice of the local doctor in charge, and this study does not interfere with any treatment of the patient.

  • sandostatinDrug

    The patient will be treated in accordance with the advice of the local doctor in charge, and this study does not interfere with any treatment of the patient

  • radiotherapyRadiation

    The patient will be treated in accordance with the advice of the local doctor in charge, and this study does not interfere with any treatment of the patient

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. clinical outcome: overall survivalTime frame: 30 yeas

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • China Acromegaly Organization

    Guangzhou, Guangdong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.